Fluoroquinolone Resistance Prevalence Study (FRE)
Exploratory Study of Fluoroquinolone Resistance for Patients Undergoing Autologous Hematopoietic Stem Cell (HSC) Transplantation in the Treatment of Multiple Myeloma
Sponsor: Hackensack Meridian Health
Terminated
Discontinued Recruitment
Other terminated trials from Hackensack Meridian Health
This observational or N/A phase trial investigates Multiple Myeloma and is currently terminated or withdrawn. Hackensack Meridian Health leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Jun 2025 — Sep 2025 [monthly]
Terminated
Status: Active Not Recruiting → Terminated
-
Mar 2025 — Jun 2025 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Mar 2024 — Jul 2024 [monthly]
Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Recruiting
-
May 2023 — Feb 2024 [monthly]
Recruiting
First recorded
Jul 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hackensack Meridian Health
For direct contact, visit the study record on ClinicalTrials.gov .